Stockreport

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next gener [Read more]